Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-24
2006-10-24
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S252130, C514S253010, C514S253040, C514S253090, C514S254010, C514S254040, C514S254050, C514S319000, C514S320000, C514S321000, C514S326000, C514S333000, C514S362000, C514S364000, C514S366000, C514S372000, C514S373000, C514S374000, C546S112000, C546S193000, C546S198000, C546S200000, C546S201000, C546S208000, C546S209000, C546S256000, C546S268400, C546S276400
Reexamination Certificate
active
07125887
ABSTRACT:
Pyrrolidine compounds of Formula (I), (wherein R1, R2, R3, R4, R5, R6a, R6b, R7and R8are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described
REFERENCES:
patent: 6124319 (2000-09-01), MacCoss et al.
patent: 6136827 (2000-10-01), Caldwell et al.
patent: 6140349 (2000-10-01), Caldwell et al.
patent: 6166037 (2000-12-01), Budhu et al.
patent: 6248755 (2001-06-01), Chapman et al.
patent: 6265434 (2001-07-01), Caldwell et al.
patent: 6358979 (2002-03-01), Finke et al.
patent: 6399619 (2002-06-01), Berk et al.
patent: 6432981 (2002-08-01), Finke et al.
patent: 6472410 (2002-10-01), Finke et al.
patent: 6498161 (2002-12-01), Caldwell et al.
patent: 6500844 (2002-12-01), Finke et al.
patent: 6506777 (2003-01-01), Finke et al.
patent: 6511994 (2003-01-01), Kim et al.
patent: 6531484 (2003-03-01), Willoughby et al.
patent: 6538002 (2003-03-01), Finke et al.
patent: 2002/0094989 (2002-07-01), Hale et al.
Search result 1.
Search result 2.
T.J. Schall, “Biology of the Rantes/SIS Cytokine Family”, Cytokine, vol. 3. No. 3, pp. 165-183 (1991).
P.M. Murphy et al., “The Molecular Biology of Leukocyte Chemoattractant Receptors”, Annu. Rev. Immunol., vol. 12, pp. 593-655 (1994).
H. Deng et al., “Identification of a Major Co-Receptor for Primary Isolates of HIV-1”, Nature, vol. 381, pp. 661-666 (1996).
R. Horuk, “Molecular Properties of the Chemokine Receptor Family”, Trends, Pharm. Sci., vol. 15, pp. 159-165 (1994).
A Ben-Baruch et al., “Monocyte Chemotactic Protein-3 (MCP3) Interacts with Multiple Leukocyte Receptors”, J. Biol. Chem., vol. 270, No. 38, pp. 22123-22128 (1995).
K. Neote et al., “Molecular Cloning, Functional Expression, and Signaling Characteristics of a C-C Chemokine Receptor”, Cell, vol. 72, pp. 415-425 (1993).
C. Combadiere et al., “Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor”, J. Biol. Chem., vol. 270, pp. 16491-16494 (1995).
C.A. Power et al., “Molecular Cloning and Functional Expression of a Novel CC Chemokine Receptor cDNA from a Human Basophilic Cell Line”, J. Biol. Chem., vol. 270, pp. 19495-19500 (1995).
M. Samson et al., “Molecular Cloning and Functional Expression of a New Human CC-Chemokine Receptor Gene”, Biochemistry, vol. 35, pp. 3362-3367 (1996).
A. Chaudhuri et al., “Expression of the Duffy Antigen in K562 Cells”, J. Biol. Chem, vol. 269, No. 11, pp. 7835-7838 (1994).
H. Kita et al., “Chemokines Active on Eosinophils: Potential Roles in Allergic Inflammation”, J. Exp. Med, vol. 183, pp. 2421-2426 (1996).
D.H. Smith et al., “Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen”, Science, vol. 238, pp. 1704-1707 (1987).
T. Dragic et al., “HIV-1 entry into CD4 Cells is Mediated by the Chemokine Receptor CC-CKR-5”, Nature, vol. 381, pp. 667-668 (1996).
L. Wu, “CD4-Induced Interaction of Primary HIV-1 GP120 Glycoproteins with the Chemokine Receoptor CCR-5”, Nature, vol. 384, pp. 179-183 (1996).
A. Trkola et al . . . , “CD4-Dependent, Antibody-Sensitive Interactions Between HIV-1 and its co-receptor CCR-5,”, Nature, vol. 384, pp. 184-187 (1996).
M. Samson et al., “Resistance to HIV-1 Infection in Caucasian Individuals Bearing Mutant Alleles of the CCR-5 Chemokine Receptor Gene”, Nature, vol. 382, pp. 722-725 (1996).
L. Zhang et al., “HIV-1 Subtype and Second-Receptor Use”, Nature, vol. 383, pp. 768 (1996).
Y. Huang et al., “The Role of a Mutuant CCR5 Allele in HIV-1 Transmission and Disease Progression”, Nature Medicine, vol. 2, pp. 1240-1241 (1996).
J.A. Levy, “Infection by Human Immunodeficiency Virus, CD4 is Not Enough”, The New England Journal of Medicine, vol. 335, pp. 1528-1530 (1996).
Caldwell Charles G.
Chapman Kevin T.
Chen Liya
Cheng, legal representative Yuan
Gentry Amy
Camara Valerie J.
Chang Celia
Merck & Co. , Inc.
Walton Kenneth R.
LandOfFree
Pyrrolidine modulators of CCR5 chemokine receptor activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolidine modulators of CCR5 chemokine receptor activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidine modulators of CCR5 chemokine receptor activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3674108